

Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV

New England Journal of Medicine

385, 2348-2360

DOI: [10.1056/nejmoa2105290](https://doi.org/10.1056/nejmoa2105290)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Effectiveness of Covid-19 Vaccination Against Risk of Symptomatic Infection, Hospitalization, and Death Up to 9 Months: A Swedish Total-Population Cohort Study. SSRN Electronic Journal, 0, , .	0.4	36
3	Immunogenicity and safety of AZD1222 (ChAdOx1 nCoV-19) against SARS-CoV-2 in Japan: a double-blind, randomized controlled phase 1/2 trial. International Journal of Infectious Diseases, 2022, 114, 165-174.	1.5	18
4	Interspecies Jumping of Bat Coronaviruses. Viruses, 2021, 13, 2188.	1.5	16
5	Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn. Gene Reports, 2021, 25, 101417.	0.4	15
6	Effectiveness and safety of SARS-CoV-2 vaccine in real-world studies: a systematic review and meta-analysis. Infectious Diseases of Poverty, 2021, 10, 132.	1.5	244
9	PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio. Vaccines, 2021, 9, 1381.	2.1	26
10	VLP-Based COVID-19 Vaccines: An Adaptable Technology against the Threat of New Variants. Vaccines, 2021, 9, 1409.	2.1	22
11	Boosting immunity to COVID-19 vaccines. Nature Medicine, 2021, 27, 1874-1875.	15.2	56
13	Heterologous Vaccination for Preparing COVID-19 Pandemic. Korean Journal of Medicine, 2021, 96, 450-454.	0.1	0
14	Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine. Vaccines, 2022, 10, 86.	2.1	62
15	A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant. International Journal of Biological Sciences, 2022, 18, 889-900.	2.6	40
18	Adenovirus-based vaccines as a platform for pandemic preparedness against emerging viral pathogens. Molecular Therapy, 2022, 30, 1822-1849.	3.7	24
19	Association Between Suggestive Symptom of Restless Legs Syndrome and COVID-19 Vaccination: A Pilot Study. Journal of Sleep Medicine, 0, , .	0.4	1
22	Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet, The, 2022, 399, 461-472.	6.3	69
23	Risk of SARS-CoV-2 Reinfection and COVID-19 Hospitalisation in Individuals With Natural- and Hybrid Immunity: A Retrospective, Total Population Cohort Study in Sweden. SSRN Electronic Journal, 0, , .	0.4	13
24	Hypertension Is Associated With Antibody Response and Breakthrough Infection in Health Care Workers Following Vaccination With Inactivated SARS-CoV-2. SSRN Electronic Journal, 0, , .	0.4	2
25	Will the COVID-19 pandemic end with the Delta and Omicron variants?. Environmental Chemistry Letters, 2022, 20, 2215-2225.	8.3	36
26	Safety of COVID-19 vaccination in patients with previous cerebral venous sinus thrombosis. Thrombosis Research, 2022, 209, 84-85.	0.8	6

#	ARTICLE	IF	CITATIONS
27	Evaluating Antibody Mediated Protection against Alpha, Beta, and Delta SARS-CoV-2 Variants of Concern in K18-hACE2 Transgenic Mice. <i>Journal of Virology</i> , 2022, 96, jvi0218421.	1.5	14
28	COVID-19 Vaccines. <i>Infectious Disease Clinics of North America</i> , 2022, 36, 481-494.	1.9	13
30	It is time to include real-world effectiveness data on medicinal product labels. <i>Lancet Respiratory Medicine</i> , 2022, , .	5.2	1
31	SARS-CoV-2 Variants of Concern and Variants of Interest Receptor Binding Domain Mutations and Virus Infectivity. <i>Frontiers in Immunology</i> , 2022, 13, 825256.	2.2	54
32	Imaging and Clinical Features of COVID-19 Breakthrough Infections: A Multicenter Study. <i>Radiology</i> , 2022, 303, 682-692.	3.6	44
33	Vaccination against COVID-19 among people living with HIV: A cross-sectional survey in Chittoor District of Andhra Pradesh, India. <i>Current Medical Issues</i> , 2022, 20, 32.	0.1	1
34	Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden. <i>Lancet, The</i> , 2022, 399, 814-823.	6.3	196
35	Roadmap for Sex-Responsive Influenza and COVID-19 Vaccine Research in Older Adults. <i>Frontiers in Aging</i> , 2022, 3, .	1.2	9
36	Moyamoya disease with Sjogren disease and autoimmune thyroiditis presenting with left intracranial hemorrhage after messenger RNA-1273 vaccination. <i>Medicine (United States)</i> , 2022, 101, e28756.	0.4	7
37	COVID-19 vaccine effectiveness among immunocompromised populations: a targeted literature review of real-world studies. <i>Expert Review of Vaccines</i> , 2022, 21, 435-451.	2.0	48
38	Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico. <i>New England Journal of Medicine</i> , 2022, 386, 531-543.	13.9	274
40	Randomised Clinical Trials of COVID-19 Vaccines: Do Adenovirus-Vector Vaccines Have Beneficial Non-Specific Effects?. <i>SSRN Electronic Journal</i> , 0, , .	0.4	10
41	Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines. <i>Npj Vaccines</i> , 2022, 7, 22.	2.9	14
42	COVID-19 vaccine development based on recombinant viral and bacterial vector systems: combinatorial effect of adaptive and trained immunity. <i>Journal of Microbiology</i> , 2022, 60, 321-334.	1.3	12
43	Antibody response to COVID-19 vaccination in patients with lymphoma. <i>International Journal of Hematology</i> , 2022, 115, 728-736.	0.7	13
45	SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic. <i>Frontiers of Medicine</i> , 2022, 16, 185-195.	1.5	11
46	Humoral response and breakthrough infections with SARS-CoV-2 B.1.617.2 variant in vaccinated maintenance hemodialysis patients. <i>Journal of Nephrology</i> , 2022, 35, 1479-1487.	0.9	18
47	A review on COVID-19 transmission, epidemiological features, prevention and vaccination. <i>Medical Review</i> , 2022, 2, 23-49.	0.3	3

#	ARTICLE	IF	CITATIONS
48	Susac Syndrome Following COVID-19 Vaccination: A Case Report. <i>Vaccines</i> , 2022, 10, 363.	2.1	12
49	Adverse Events Reporting Quality of Randomized Controlled Trials of COVID-19 Vaccine Using the CONSORT Criteria for Reporting Harms: A Systematic Review. <i>Vaccines</i> , 2022, 10, 313.	2.1	5
51	COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 385-401.	12.5	135
52	Cutaneous adverse reactions to coronavirus vaccines: A Saudi nationwide study. <i>Dermatologic Therapy</i> , 2022, , e15452.	0.8	7
53	Seroconversion rates among different designs of COVID-19 vaccines: a network meta-analysis of randomized controlled trials. <i>F1000Research</i> , 0, 11, 299.	0.8	0
54	Waning COVID-19 Vaccine Effectiveness for BNT162b2 and CoronaVac in Malaysia: An Observational Study. <i>International Journal of Infectious Diseases</i> , 2022, 119, 69-76.	1.5	48
55	Onset of Oral Lichenoid Lesions and Oral Lichen Planus Following COVID-19 Vaccination: A Retrospective Analysis of about 300,000 Vaccinated Patients. <i>Vaccines</i> , 2022, 10, 480.	2.1	15
56	Anti-SARS-CoV-2 Antibody Responses 5 Months Post Complete Vaccination of Moroccan Healthcare Workers. <i>Vaccines</i> , 2022, 10, 465.	2.1	5
58	Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-7.	1.4	12
59	COVID-19 Vaccination within the Context of Reactogenicity and Immunogenicity of ChAdOx1 Vaccine Administered to Teachers in Poland. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 3111.	1.2	1
60	COVID-19 mRNA vaccine in patients with lymphoid malignancy or anti-CD20 antibody therapy: a systematic review and meta-analysis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2022, , .	0.2	7
61	Biosafety assessment of delivery systems for clinical nucleic acid therapeutics. <i>Biosafety and Health</i> , 2022, 4, 105-117.	1.2	15
62	Caring for older adults during the COVID-19 pandemic. <i>Clinical Microbiology and Infection</i> , 2022, 28, 785-791.	2.8	21
63	Utilization of Viral Vector Vaccines in Preparing for Future Pandemics. <i>Vaccines</i> , 2022, 10, 436.	2.1	4
64	Association of severity and mortality of Covid-19 cases among acute kidney injury and sexual dimorphism. <i>Molecular Biology Reports</i> , 2022, 49, 6753-6762.	1.0	1
65	Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. <i>JCI Insight</i> , 2022, 7, .	2.3	26
66	Effectiveness of COVID-19 vaccines in older adults in Colombia: a retrospective, population-based study of the ESPERANZA cohort. <i>The Lancet Healthy Longevity</i> , 2022, 3, e242-e252.	2.0	54
67	Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 781-790.	4.6	191

#	ARTICLE	IF	CITATIONS
68	Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena. <i>Viruses</i> , 2022, 14, 759.	1.5	41
69	Factors Associated with Non-Severe Adverse Reactions after Vaccination against SARS-CoV-2: A Cohort Study of 908,869 Outpatient Vaccinations in Germany. <i>Vaccines</i> , 2022, 10, 566.	2.1	11
70	SARS-CoV-2 vaccine in patients with thymic epithelial tumours with and without active or pre-existing autoimmune disorders: Brief report of a TYME network safety analysis. <i>European Journal of Cancer</i> , 2022, 166, 202-207.	1.3	4
71	Case for mandatory COVID-19 vaccinations for workers in health and aged care settings: a guide for leaders. <i>BMJ Leader</i> , 2022, 6, 143-145.	0.8	1
72	Immunogenicity after Second ChAdOx1 nCoV-19 (AZD1222) Vaccination According to the Individual Reactogenicity, Health Status and Lifestyle. <i>Vaccines</i> , 2021, 9, 1473.	2.1	4
73	Vaccines and Vaccination against SARS-CoV-2: Considerations for the Older Population. <i>Vaccines</i> , 2021, 9, 1435.	2.1	8
74	Criteria for judging the immune markers of COVID-19 disease vaccines. <i>MedComm</i> , 2022, 3, 1-12.	3.1	3
77	Prevalence and Safety of COVID-19 Vaccination in Community-Dwelling People with Dementia: Findings from a Tertiary Memory Clinic in Italy. <i>Journal of Alzheimer's Disease</i> , 2022, 87, 1467-1474.	1.2	2
78	Drop the Needle; A Temperature Stable Oral Tablet Vaccine Is Protective against Respiratory Viral Pathogens. <i>Vaccines</i> , 2022, 10, 593.	2.1	7
80	Acute Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccine: A Case Report and Literature Review. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 856991.	1.1	6
81	Efficacy and effectiveness of covid-19 vaccine - absolute vs. relative risk reduction. <i>Expert Review of Vaccines</i> , 2022, 21, 873-875.	2.0	7
82	Accelerating clinical trial development in vaccinology: COVID-19 and beyond. <i>Current Opinion in Immunology</i> , 2022, 76, 102206.	2.4	4
83	Impact of Remdesivir Incorporation along the Primer Strand on SARS-CoV-2 RNA-Dependent RNA Polymerase. <i>Journal of Chemical Information and Modeling</i> , 2022, 62, 2456-2465.	2.5	7
84	A Systematic Review of Coronavirus Disease 2019 Vaccine Efficacy and Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Disease. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	62
85	Therapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers. <i>Pharmaceutics</i> , 2022, 14, 867.	2.0	9
86	SARS-CoV-2 Spike Protein Expression In Vitro and Hematologic Effects in Mice Vaccinated With AZD1222 (ChAdOx1 nCoV-19). <i>Frontiers in Immunology</i> , 2022, 13, 836492.	2.2	8
87	Impact of prior vaccination on clinical outcomes of patients with COVID-19. <i>Emerging Microbes and Infections</i> , 2022, 11, 1316-1324.	3.0	7
88	Real-world evidence from over one million COVID-19 vaccinations is consistent with reactivation of the varicella-zoster virus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1342-1348.	1.3	28

#	ARTICLE	IF	CITATIONS
89	Validation and performance of a multiplex serology assay to quantify antibody responses following SARS-CoV-2 infection or vaccination. <i>Clinical and Translational Immunology</i> , 2022, 11, e1385.	1.7	10
90	Covid-19: virology, variants, and vaccines. , 2022, 1, e000040.		24
91	Effectiveness of COVID-19 Vaccines in the General Population of an Italian Region before and during the Omicron Wave. <i>Vaccines</i> , 2022, 10, 662.	2.1	17
92	Clinical and Immunologic Efficacy of the Recombinant Adenovirus Type-5-Vectored (CanSino Bio) Vaccine in University Professors during the COVID-19 Delta Wave. <i>Vaccines</i> , 2022, 10, 656.	2.1	4
93	Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4902.	1.8	9
94	Determinants of the Hesitancy toward COVID-19 Vaccination in Eastern European Countries and the Relationship with Health and Vaccine Literacy: A Literature Review. <i>Vaccines</i> , 2022, 10, 672.	2.1	35
95	Adverse Audio-Vestibular Effects of Drugs and Vaccines Used in the Treatment and Prevention of COVID-19: A Review. <i>Audiology Research</i> , 2022, 12, 224-248.	0.8	6
96	Cytokine Responses to Adenovirus and Adenovirus Vectors. <i>Viruses</i> , 2022, 14, 888.	1.5	18
97	An overview of current drugs and prophylactic vaccines for coronavirus disease 2019 (COVID-19). <i>Cellular and Molecular Biology Letters</i> , 2022, 27, 38.	2.7	11
98	Frequency and Nuisance Level of Adverse Events in Individuals Receiving Homologous and Heterologous COVID-19 Booster Vaccine. <i>Vaccines</i> , 2022, 10, 754.	2.1	10
99	Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination. <i>Scientific Reports</i> , 2022, 12, 7961.	1.6	7
100	Analysis of Older Adults Visiting the Emergency Department with Fever as a Suspected Covid-19 Vaccine-Related Adverse Reaction: A Retrospective Multicenter Study. <i>Journal of Infection and Chemotherapy</i> , 2022, 28, 1159-1164.	0.8	2
101	Analyzing COVID-19 vaccine efficacy in vulnerable communities: efforts beyond addressing vaccine inequity. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1053-1054.	2.8	1
102	Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults. <i>New England Journal of Medicine</i> , 2022, 386, 2097-2111.	13.9	147
103	Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants. <i>Nature Communications</i> , 2022, 13, 2674.	5.8	26
104	Trajectory of long covid symptoms after covid-19 vaccination: community based cohort study. <i>BMJ, The</i> , 2022, 377, e069676.	3.0	214
105	A SARS-CoV-2 outbreak associated with vaccine breakthrough in an acute care hospital. <i>American Journal of Infection Control</i> , 2022, 50, 1006-1012.	1.1	3
106	Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study. <i>Vaccines</i> , 2022, 10, 807.	2.1	3

#	ARTICLE	IF	CITATIONS
107	Dermatomyositis Post COVID-19 Vaccine: A Case Report. Open Journal of Rheumatology and Autoimmune Diseases, 2022, 12, 65-70.	0.1	0
108	COVID-19 and Cancer: Special Considerations for Patients Receiving Immunotherapy and Immunosuppressive Cancer Therapies. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 176-188.	1.8	7
109	A Single Dose of the Deactivated Rabies-Virus Vected COVID-19 Vaccine, CORAVAX, Is Highly Efficacious and Alleviates Lung Inflammation in the Hamster Model. Viruses, 2022, 14, 1126.	1.5	2
110	Effectiveness of heterologous and homologous covid-19 vaccine regimens: living systematic review with network meta-analysis. BMJ, The, 0, , e069989.	3.0	78
111	Hypertension is associated with antibody response and breakthrough infection in health care workers following vaccination with inactivated SARS-CoV-2. Vaccine, 2022, 40, 4046-4056.	1.7	24
112	Severity of COVID-19 after Vaccination among Hemodialysis Patients. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 843-850.	2.2	34
113	Nonhuman primate models for evaluation of SARS-CoV-2 vaccines. Expert Review of Vaccines, 2022, 21, 1055-1070.	2.0	1
114	SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition. Cancers, 2022, 14, 2796.	1.7	9
115	SARS-CoV-2 vaccine challenge based on spike glycoprotein against several new variants. Clinical and Experimental Vaccine Research, 2022, 11, 173.	1.1	0
116	COVID-19 Vaccine Booster Significantly Decreases the Risk of Intensive Care Unit Hospitalization in Heart Failure Patients During the Omicron Variant Wave: A Population-Based Study. SSRN Electronic Journal, 0, , .	0.4	0
119	Adenoviral-Vectored Centralized Consensus Hemagglutinin Vaccine Provides Broad Protection against H2 Influenza a Virus. Vaccines, 2022, 10, 926.	2.1	2
120	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial. Lancet, The, 2022, 399, 2212-2225.	6.3	23
121	Plausibility of Claimed Covid-19 Vaccine Efficacies by Age: A Simulation Study. American Journal of Therapeutics, 2022, 29, e495-e499.	0.5	3
122	Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection. Nature Communications, 2022, 13, .	5.8	28
123	Immunizing the imperfect immune system. Annals of Allergy, Asthma and Immunology, 2022, 129, 562-571.e1.	0.5	16
124	Individual-level social capital and COVID-19 vaccine hesitancy in Japan: a cross-sectional study. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	10
125	Rapid evaluation of COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 variants by analysis of genetic distance. Nature Medicine, 2022, 28, 1715-1722.	15.2	29
126	Case report of acute encephalitis following the AstraZeneca COVID-19 vaccine. International Journal of Rheumatic Diseases, 2022, 25, 950-956.	0.9	9

#	ARTICLE	IF	CITATIONS
127	Fever following Covid-19 vaccination in subjects with Brugada syndrome: Incidence and management. <i>Journal of Cardiovascular Electrophysiology</i> , 0, , .	0.8	6
128	Coronavirus Disease 2019 Vaccinations in Patients With Chronic Liver Disease and Liver Transplant Recipients: An Update. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	8
129	Comparative effectiveness and durability of COVID-19 vaccination against death and severe disease in an ongoing nationwide mass vaccination campaign. <i>Journal of Medical Virology</i> , 2022, 94, 5044-5050.	2.5	27
130	Misdiagnosis of Reactive Lymphadenopathy Remotely After COVID-19 Vaccination: A Case Report and Literature Review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
131	Presence of SARS-CoV-2 Antibodies among Vietnamese Healthcare Workers by Dosing Interval for ChAdOx1 nCoV-19 Vaccine. <i>Clinical Infectious Diseases</i> , 0, , .	2.9	1
132	Safety and immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme: Open label phase I and phase IIa clinical trials. <i>Vaccine</i> , 2022, 40, 4220-4230.	1.7	27
133	Long-term antibody response following SPUTNIK V primary vaccination in healthcare workers with and without history of SARS-CoV-2 infection: Prospective cohort study from a hospital in Argentina. <i>Vaccine: X</i> , 2022, 11, 100187.	0.9	4
134	Safety and Immunogenicity of SII-NVX-CoV2373 (COVID-19 Vaccine) In Adults in a Phase 2/3, Observer-Blind, Randomised, Controlled Study. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2
135	Impact of BNT162b2 mRNA Vaccination on the Development of Short and Long-Term Vaccine-Related Adverse Events in Inflammatory Bowel Disease: A Multi-Center Prospective Study. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	1
137	Immune Response in Regard to Hypersensitivity Reactions after COVID-19 Vaccination. <i>Biomedicines</i> , 2022, 10, 1641.	1.4	3
138	Viral Vector Vaccine Development and Application during the COVID-19 Pandemic. <i>Microorganisms</i> , 2022, 10, 1450.	1.6	28
139	COVID-19 vaccination efficacy in numbers including SARS-CoV-2 variants and age comparison: a meta-analysis of randomized clinical trials. <i>Annals of Clinical Microbiology and Antimicrobials</i> , 2022, 21, .	1.7	6
140	An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females. <i>EBioMedicine</i> , 2022, 81, 104128.	2.7	8
141	Quantifying the immunological distinctiveness of emerging SARS-CoV-2 variants in the context of prior regional herd exposure. , 0, , .		0
142	Spike Mutation Profiles Associated With SARS-CoV-2 Breakthrough Infections in Delta Emerging and Predominant Time Periods in British Columbia, Canada. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	3
143	Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. <i>Annals of Internal Medicine</i> , 2022, 175, 1258-1265.	2.0	63
144	Vaccine-Related adverse events following AZD1222 (ChAdOx1-nCoV-19) Covid-19 vaccine in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	7
145	The short term safety of COVID-19 vaccines in Australia: AusVaxSafety active surveillance, February – August 2021. <i>Medical Journal of Australia</i> , 2022, 217, 195-202.	0.8	14

#	ARTICLE	IF	CITATIONS
146	The design and analysis of vaccine trials for COVID-19 for the purpose of estimating efficacy. <i>Pharmaceutical Statistics</i> , 2022, 21, 790-807.	0.7	4
147	Reactogenicity, immunogenicity, and humoral immune response dynamics after the third dose of heterologous COVID-19 vaccines in participants fully vaccinated with inactivated vaccine. <i>Expert Review of Vaccines</i> , 2022, 21, 1873-1881.	2.0	4
148	COVID-19 Vaccination and the Rate of Immune and Autoimmune Adverse Events Following Immunization: Insights From a Narrative Literature Review. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	24
149	Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine. <i>Vaccines</i> , 2022, 10, 1071.	2.1	14
151	Depression, aging, and immunity: implications for COVID-19 vaccine immunogenicity. <i>Immunity and Ageing</i> , 2022, 19, .	1.8	6
152	The Impact of D614G Mutation of SARS-COV-2 on the Efficacy of Anti-viral Drugs: A Comparative Molecular Docking and Molecular Dynamics Study. <i>Current Microbiology</i> , 2022, 79, .	1.0	36
153	Immunogenicity, efficacy and safety of COVID-19 vaccines: an update of data published by 31 December 2021. <i>International Immunology</i> , 2022, 34, 595-607.	1.8	19
154	Persistence of immunity against Omicron BA.1 and BA.2 variants following homologous and heterologous COVID-19 booster vaccines in healthy adults after a two-dose AZD1222 vaccination. <i>International Journal of Infectious Diseases</i> , 2022, 122, 793-801.	1.5	17
155	Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis. <i>Expert Review of Vaccines</i> , 2022, 21, 1301-1318.	2.0	12
156	Insights into COVID-19 vaccines development: Translation from benchside to bedside. <i>Health Sciences Review</i> , 2022, 4, 100040.	0.6	1
157	Population-wide persistent hemostatic changes after vaccination with ChAdOx1-S. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	11
159	Report of Adverse Effects Following Population-Wide COVID-19 Vaccination: A Comparative Study between Six Different Vaccines in Baja-California, Mexico. <i>Vaccines</i> , 2022, 10, 1196.	2.1	3
161	Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: Case characteristics and associations. <i>Vaccine</i> , 2022, 40, 5585-5593.	1.7	3
162	The effectiveness of COVID-19 vaccines in reducing the incidence, hospitalization, and mortality from COVID-19: A systematic review and meta-analysis. <i>Frontiers in Public Health</i> , 0, 10, .	1.3	70
163	The SARS-CoV-2 Variants and their Impacts. <i>Journal of Pure and Applied Microbiology</i> , 2022, 16, 1409-1424.	0.3	3
164	A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	13
165	Recent Developments in the Understanding of Immunity, Pathogenesis and Management of COVID-19. <i>International Journal of Molecular Sciences</i> , 2022, 23, 9297.	1.8	4
166	COVID-19 Vaccine Clinical Trials: A Bird's Eye Perspective. <i>Cureus</i> , 2022, , .	0.2	0

#	ARTICLE	IF	CITATIONS
168	Immunogenicity and reactogenicity of heterologous immunization against SARS CoV-2 using Sputnik V, ChAdOx1-S, BBIBP-CorV, Ad5-nCoV, and mRNA-1273. <i>Cell Reports Medicine</i> , 2022, 3, 100706.	3.3	23
169	SARS-CoV-2 and Immunity: Natural Infection Compared with Vaccination. <i>International Journal of Molecular Sciences</i> , 2022, 23, 8982.	1.8	4
170	Fitting the reproduction number from UK coronavirus case data and why it is close to 1. <i>Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences</i> , 2022, 380, .	1.6	7
171	Immunogenicity evaluation of ChAdox1 nCoV-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	0
172	Dynamics and persistence of severe acute respiratory syndrome coronavirus-2 antibody response after double dose and the third dose with BBV-152 and AZD1222 vaccines: A prospective, longitudinal cohort study. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	3
173	The current status of COVID-19 vaccines. A scoping review. <i>Drug Discovery Today</i> , 2022, 27, 103336.	3.2	7
174	ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants. <i>Nature Communications</i> , 2022, 13, .	5.8	23
175	Efficacy of Approved Versus Unapproved Vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Randomized Blinded Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	2
176	Active Safety Surveillance of Four Types of COVID-19 Vaccines: A National Study from Jordan. <i>Clinical Drug Investigation</i> , 2022, 42, 813-827.	1.1	12
177	New-onset IgA nephropathy following COVID-19 vaccination. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2023, 116, 26-39.	0.2	20
178	Immunogenicity of ChAdOx1-nCoV-19 vaccine in solid malignancy patients by treatment regimen versus healthy controls: A prospective, multicenter observational study. <i>EClinicalMedicine</i> , 2022, 52, 101608.	3.2	8
180	Lessons from a large-scale COVID-19 vaccine trial. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	3
181	Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: a systematic review and meta-analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	15
183	Assessing the Robustness of SARS-CoV-2 Vaccine Efficacy Trials: Systematic Review and Meta-Analysis. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
184	Diaphragmatic Dysfunction due to Neuralgic Amyotrophy After SARS-CoV-2 Vaccination: A Case Report. <i>Journal of Korean Medical Science</i> , 2022, 37, .	1.1	4
185	Breakthrough COVID-19 Infection During the Delta Variant Dominant Period: Individualized Care Based on Vaccination Status Is Needed. <i>Journal of Korean Medical Science</i> , 2022, 37, .	1.1	7
186	COVID-19 Vaccine Effectiveness and the Evidence on Boosters: A Systematic Review (with Partial) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.4	2
187	Cellular Immunology: Transcriptional Basis of B and T Cell Lineages and Memory Cells â€œ T Cell Memory to Viral Infections. , 2022, , .		0

#	ARTICLE	IF	CITATIONS
188	Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation. <i>Viruses</i> , 2022, 14, 1916.	1.5	7
190	Thrombosis after SARS-CoV2 infection or COVID-19 vaccination: will a nonpathologic anti-PF4 antibody be a solution?â€”A narrative review. <i>Journal of Bio-X Research</i> , 2022, 5, 97-103.	0.3	1
191	Audio-Vestibular Side Effects of Drugs and Vaccines in Treatment of COVID-19. , 0, , .		0
192	Intranasal Immunization with Liposome-Displayed Receptor-Binding Domain Induces Mucosal Immunity and Protection against SARS-CoV-2. <i>Pathogens</i> , 2022, 11, 1035.	1.2	10
193	Virtual autopsy in SARS-CoV-2 breakthrough infection: a case report. <i>Forensic Imaging</i> , 2022, 30, 200520.	0.4	4
194	A prospective study on myocardial injury after <sc>BNT162b2 mRNA COVID</sc>â€™19 fourth dose vaccination in healthy persons. <i>European Journal of Heart Failure</i> , 2023, 25, 313-318.	2.9	8
195	Postvaccinal GABAâ€™B receptor antibody encephalitis after ChAdOx1 nCoVâ€™19 vaccination. <i>Annals of Clinical and Translational Neurology</i> , 2022, 9, 1673-1678.	1.7	4
197	Evidence of the Efficacy and the Effectiveness of First Generation COVID-19 Vaccines in Clinical Trials and Real-world Studies. <i>Zoonoses</i> , 2022, 2, .	0.5	0
198	Side Effects of COVID-19 Vaccines in Patients with Inflammatory Bowel Disease in Japan. <i>Digestive Diseases and Sciences</i> , 0, , .	1.1	1
199	Case report: Sudden cardiorespiratory collapse in a healthy male after coronavirus disease 2019 vaccination at a vaccination center. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	1
200	A cross-country comparison of Covid-19 containment measures and their effects on the epidemic curves. <i>BMC Public Health</i> , 2022, 22, .	1.2	16
201	Evaluation of the T cell and B cell response following the administration of COVID-19 vaccines in Korea. <i>Journal of Microbiology, Immunology and Infection</i> , 2022, 55, 1013-1024.	1.5	6
202	An Update on Complications Associated with SARS-CoV-2 Infection and COVID-19 Vaccination. <i>Vaccines</i> , 2022, 10, 1639.	2.1	1
204	Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	18
205	Guillain-BarrÃ© syndrome in association with COVID-19 vaccination: a systematic review. <i>Immunologic Research</i> , 2022, 70, 752-764.	1.3	18
206	Study of the Side Effects of Pfizer and Oxford COVID-19 Vaccines in the Eastern Province of Saudi Arabia. <i>International Journal of General Medicine</i> , 0, Volume 15, 7547-7558.	0.8	7
207	A critical overview of current progress for COVID-19: development of vaccines, antiviralâ€™drugs, and therapeutic antibodies. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	64
208	Modelling optimal vaccination strategies against COVID-19 in a context of Gamma variant predominance in Brazil. <i>Vaccine</i> , 2022, 40, 6616-6624.	1.7	8

#	ARTICLE	IF	CITATIONS
209	COVID-19 and cellular senescence. <i>Nature Reviews Immunology</i> , 2023, 23, 251-263.	10.6	54
210	Humoral and cellular immune response over 9 months of mRNA-1273, BNT162b2 and ChAdOx1 vaccination in a University Hospital in Spain. <i>Scientific Reports</i> , 2022, 12, .	1.6	9
212	A Community Partnered Approach for Diversity in COVID-19 Vaccine Clinical Trials. <i>Journal of Clinical and Translational Science</i> , 0, , 1-19.	0.3	4
213	Effectiveness of ChAdOx1 nCoV-19 coronavirus vaccine in preventing severe disease and mortality during the second wave of pandemic: A case-case analysis from a tertiary care center in South India. <i>Journal of Acute Disease</i> , 2022, 11, 188.	0.0	1
214	Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial. <i>EBioMedicine</i> , 2022, 85, 104298.	2.7	70
215	A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 1655.	2.1	12
216	Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness. <i>Vaccines</i> , 2022, 10, 1751.	2.1	10
217	COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. <i>Journal of Biomedical Science</i> , 2022, 29, .	2.6	77
218	COVID-19 vaccine booster significantly decreases the risk of intensive care unit hospitalization in heart failure patients during the Omicron variant wave: A population-based study. <i>Frontiers in Cardiovascular Medicine</i> , 0, 9, .	1.1	3
219	Antibody and T-Cell Subsets Analysis Unveils an Immune Profile Heterogeneity Mediating Long-term Responses in Individuals Vaccinated Against SARS-CoV-2. <i>Journal of Infectious Diseases</i> , 2023, 227, 353-363.	1.9	2
222	Vaccine versus infection – COVID-19-related loss of training time in elite athletes. <i>Journal of Science and Medicine in Sport</i> , 2022, 25, 950-959.	0.6	13
223	Production and Purification of LTB-RBD: A Potential Antigen for Mucosal Vaccine Development against SARS-CoV-2. <i>Vaccines</i> , 2022, 10, 1759.	2.1	5
224	Waning of first- and second-dose ChAdOx1 and BNT162b2 COVID-19 vaccinations: a pooled target trial study of 12.9 million individuals in England, Northern Ireland, Scotland and Wales. <i>International Journal of Epidemiology</i> , 2023, 52, 22-31.	0.9	9
225	Safety and adverse events following COVID-19 vaccination among people with epilepsy: A cross-sectional study. <i>Epilepsia Open</i> , 2023, 8, 60-76.	1.3	3
226	Determinants of Antibody Response to SARS-CoV-2 Vaccines in Liver Transplant Recipients: The Role of Immunosuppression Reduction. <i>Vaccines</i> , 2022, 10, 1827.	2.1	0
227	Pandemic vaccines: a formidable challenge for pharmacovigilance. <i>Nature Reviews Drug Discovery</i> , 0, , .	21.5	0
228	Severity and Mortality Predictors of COVID-19 Patients with Thrombotic Events-Evidence from the ‘‘COVID-One’’ Hospital in Albania. <i>Vaccines</i> , 2022, 10, 1851.	2.1	0
229	Drug-induced liver injury after covid-19 mRNA vaccine: case report. <i>Colombia Medica</i> , 2022, 53, e5015187.	0.7	2

#	ARTICLE	IF	CITATIONS
230	A systematic review of current status and challenges of vaccinating children against SARS-CoV-2. <i>Journal of Infection and Public Health</i> , 2022, 15, 1212-1224.	1.9	2
231	Risk factors for critical forms of SARS-CoV-2 infection in fully vaccinated patients: a prospective observational study. <i>Pan African Medical Journal</i> , 0, 43, .	0.3	1
232	Efficacy of COVID-19 vaccines: a systematic review and network meta-analysis of phase 3 randomized controlled trials. <i>Pharmacological Reports</i> , 2022, 74, 1228-1237.	1.5	6
233	A Case Report of Exfoliative Bullous Rash Following AstraZeneca Vaccine. <i>Cureus</i> , 2022, , .	0.2	0
234	COVID-19 vaccine effectiveness against SARS-CoV-2 infection during the Delta period, a nationwide study adjusting for chance of exposure, the Netherlands, July to December 2021. <i>Eurosurveillance</i> , 2022, 27, .	3.9	6
235	Perception and safety analysis of COVID-19 vaccination in cancer patients: A multicenter, real-world study. <i>Cancer Medicine</i> , 2023, 12, 5558-5568.	1.3	2
236	Vaccines for the Prevention of Coronavirus Disease 2019 in Older Adults. <i>Infectious Disease Clinics of North America</i> , 2023, 37, 27-45.	1.9	6
237	Expert review of global real-world data on COVID-19 vaccine booster effectiveness and safety during the omicron-dominant phase of the pandemic. <i>Expert Review of Vaccines</i> , 2023, 22, 1-16.	2.0	21
238	Safety and immunogenicity of a bivalent SARS-CoV-2 recombinant protein vaccine, SCTV01C in unvaccinated adults: A randomized, double-blinded, placebo-controlled, phase I clinical trial. <i>Journal of Infection</i> , 2023, 86, 154-225.	1.7	2
239	The BBIBP-CorV inactivated COVID-19 vaccine induces robust and persistent humoral responses to SARS-CoV-2 nucleocapsid, besides spike protein in healthy adults. <i>Frontiers in Microbiology</i> , 0, 13, .	1.5	2
240	Reactogenicity and Immunogenicity of the ChAdOx1 nCoV-19 Coronavirus Disease 2019 Vaccine in South Korean Healthcare Workers. <i>Yonsei Medical Journal</i> , 0, 63, .	0.9	5
241	Developing Next-Generation Protein-Based Vaccines Using High-Affinity Glycan Ligand-Decorated Glyconanoparticles. <i>Advanced Science</i> , 2023, 10, .	5.6	5
242	Intranasal Sendai virus-based SARS-CoV-2 vaccine using a mouse model. <i>Genes To Cells</i> , 0, , .	0.5	1
243	COVID-19 Vaccination in Korea: Past, Present, and the Way Forward. <i>Journal of Korean Medical Science</i> , 2022, 37, .	1.1	20
245	A Simple Non-Invasive Score Based on Baseline Parameters Can Predict Outcome in Patients with COVID-19. <i>Vaccines</i> , 2022, 10, 2043.	2.1	0
247	Cardiovascular safety of COVID-19 vaccines in real-world studies: a systematic review and meta-analysis. <i>Expert Review of Vaccines</i> , 0, , 1-10.	2.0	6
248	Quantitative Benefit-Risk Assessment of COVID-19 Vaccines Using the Multi-Criteria Decision Analysis. <i>Vaccines</i> , 2022, 10, 2029.	2.1	3
249	Host genetics impact on SARS-CoV-2 vaccine-induced immunoglobulin levels and dynamics: The role of TP53, ABO, APOE, ACE2, HLA-A, and CRP genes. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	12

#	ARTICLE	IF	CITATIONS
250	Lot-to-lot consistency, immunogenicity, and safety of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults: A randomized, double-blind, phase IV trial. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	5
251	COVID-19 Vaccination Is Associated with a Better Outcome in Acute Ischemic Stroke Patients: A Retrospective Observational Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 6878.	1.0	3
253	ChAdOx1 NiV vaccination protects against lethal Nipah Bangladesh virus infection in African green monkeys. <i>Npj Vaccines</i> , 2022, 7, .	2.9	7
254	Effectiveness of mRNA, protein subunit vaccine and viral vectors vaccines against SARS-CoV-2 in people over 18 years old: a systematic review. <i>Expert Review of Vaccines</i> , 2023, 22, 35-53.	2.0	8
255	Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults. <i>Vaccine</i> , 2023, 41, 1834-1847.	1.7	0
257	Efficacy and safety of COVID-19 vaccines. <i>The Cochrane Library</i> , 2023, 2023, .	1.5	60
258	Mouse study of combined DNA/protein COVID-19 vaccine to boost high levels of antibody and cell mediated immune responses. <i>Emerging Microbes and Infections</i> , 2023, 12, .	3.0	2
259	AZD1222-induced nasal antibody responses are shaped by prior SARS-CoV-2 infection and correlate with virologic outcomes in breakthrough infection. <i>Cell Reports Medicine</i> , 2023, 4, 100882.	3.3	10
260	Immune-Mediated Diseases Following COVID-19 Vaccination: Report of a Teaching Hospital-Based Case-Series. <i>Journal of Clinical Medicine</i> , 2022, 11, 7484.	1.0	6
261	Recent developments in the immunopathology of COVID-19. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2023, 78, 369-388.	2.7	33
262	Les virus au service de la santé: la vaccination. <i>Medecine/Sciences</i> , 2022, 38, 1052-1060.	0.0	0
263	Effectiveness of COVID-19 Vaccines over 13 Months Covering the Period of the Emergence of the Omicron Variant in the Swedish Population. <i>Vaccines</i> , 2022, 10, 2074.	2.1	3
264	Background rate estimations for thrombosis with thrombocytopenia: challenges in evaluating rare safety signals following vaccination in real time during a pandemic. <i>BMJ Open</i> , 2023, 13, e063645.	0.8	1
265	COVID-19 in Latin America: A Snapshot in Time and the Road Ahead. <i>Infectious Diseases and Therapy</i> , 2023, 12, 389-410.	1.8	6
266	Headache attributed to SARS-CoV-2 infection, vaccination and the impact on primary headache disorders of the COVID-19 pandemic: A comprehensive review. <i>Cephalalgia</i> , 2023, 43, 033310242211313.	1.8	20
268	Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
269	Efficacy of Vaccine Protection Against COVID-19 Virus Infection in Patients with Chronic Liver Diseases. <i>Journal of Clinical and Translational Hepatology</i> , 2023, 000, 000-000.	0.7	0
270	Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV). <i>Pathogens</i> , 2023, 12, 154.	1.2	14

#	ARTICLE	IF	CITATIONS
271	Infection by SARS-CoV-2 with alternate frequencies of mRNA vaccine boosting. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	13
272	Characteristics, outcomes, and risk factors for in-hospital mortality of COVID-19 patients: A retrospective study in Thailand. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
273	COVID-19 Vaccines—All You Want to Know. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2023, 44, 143-172.	0.8	4
274	Safety and immunogenicity of SII-NVX-CoV2373 (COVID-19 vaccine) in adults in a phase 2/3, observer-blind, randomised, controlled study. , 2023, 10, 100139.		7
275	Acute adverse events of Sars-CoV2 vaccines: Experiences from a health care worker vaccination campaign in two municipal hospitals in northwest Germany. <i>Vaccine: X</i> , 2023, 13, 100257.	0.9	0
276	A Comprehensive Analysis of COVID-19 Vaccine Discourse by Vaccine Brand on Twitter in Korea: Topic and Sentiment Analysis. <i>Journal of Medical Internet Research</i> , 0, 25, e42623.	2.1	6
277	Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience. <i>Viruses</i> , 2023, 15, 118.	1.5	18
279	An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines. <i>Vaccines</i> , 2023, 11, 51.	2.1	9
280	Impact of Improper Storage of ChAdOx1-S (AstraZeneca) Vaccine on Its Efficacy and Safety. <i>Vaccines</i> , 2023, 11, 93.	2.1	0
281	A Study on The Efficacy of Vaccination in Elderly Patients with Breakthrough COVID-19 Infection. <i>Korean Journal of Clinical Geriatrics</i> , 2022, 23, 115-122.	0.3	0
282	Efficacy of mRNA and Inactivated Whole Virus Vaccines Against COVID-19 in Patients with Chronic Respiratory Diseases. <i>International Journal of COPD</i> , 0, Volume 18, 47-56.	0.9	6
283	The Outcome of BNT162b2, ChAdOx1-Sand mRNA-1273 Vaccines and Two Boosters: A Prospective Longitudinal Real-World Study. <i>Viruses</i> , 2023, 15, 326.	1.5	1
284	Cohort event monitoring for safety signal detection in adult individuals 18 years and above after immunisation with coronavirus disease 2019 vaccines in Nigeria. <i>Nigerian postgraduate medical journal, The</i> , 2023, 30, 18.	0.1	0
285	The coverage of medical injuries in company trial informed consent forms. <i>International Journal of Risk and Safety in Medicine</i> , 2023, 34, 121-128.	0.3	3
286	Adverse events following the first, second and third doses of a COVID-19 vaccine in hemodialysis patients. <i>Renal Failure</i> , 2023, 45, .	0.8	5
288	Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials. <i>JAMA Network Open</i> , 2023, 6, e2251974.	2.8	12
289	SARS-CoV-2 infection and immune responses. <i>AIMS Microbiology</i> , 2023, 9, 245-276.	1.0	2
290	COVID-19 Vaccination in Korea. <i>Infection and Chemotherapy</i> , 2023, 55, 135.	1.0	9

#	ARTICLE	IF	CITATIONS
291	SARS-CoV-2 Vaccination-Induced Immunogenicity in Heart Transplant Recipients. <i>Transplant International</i> , 0, 36, .	0.8	1
292	Tracking the COVID-19 vaccines: The global landscape. <i>Human Vaccines and Immunotherapeutics</i> , 2023, 19, .	1.4	17
293	Priority age targets for COVID-19 vaccination in Ethiopia under limited vaccine supply. <i>Scientific Reports</i> , 2023, 13, .	1.6	3
294	Adenoviral vectored vaccination protects against Crimean-Congo Haemorrhagic Fever disease in a lethal challenge model. <i>EBioMedicine</i> , 2023, 90, 104523.	2.7	7
295	Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials. <i>Lancet Microbe</i> , The, 2023, 4, e236-e246.	3.4	46
296	Risk of disease relapse, safety and tolerability of SARS-CoV-2 vaccination in patients with chronic inflammatory neuropathies. <i>European Journal of Neurology</i> , 0, , .	1.7	0
297	Vaccine confidence among those living with allergy during the COVID pandemic (ACCORD): A scoping review. , 2023, 2, 100079.		2
298	Propagation and immunological characterization of coxsackievirus A10 in a serum-free HEK293A cell culture system. <i>Virus Research</i> , 2023, 329, 199101.	1.1	1
300	<i>In silico</i> design of a multi-epitope vaccine against the spike and the nucleocapsid proteins of the Omicron variant of SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 11748-11762.	2.0	4
301	Impact of chronic liver disease on SARS-CoV-2 infection outcomes: Roles of stage, etiology and vaccination. <i>World Journal of Gastroenterology</i> , 0, 29, 800-814.	1.4	5
302	Persistence of the immune response after two doses of ChAdOx1 nCov-19 (AZD1222): 1 year of follow-up of two randomized controlled trials. <i>Clinical and Experimental Immunology</i> , 2023, 211, 280-287.	1.1	2
304	A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen. <i>Vaccine</i> , 2023, 41, 1694-1702.	1.7	5
306	COVID-19 Vaccination and the Incidence of De Novo or Recurrent Rheumatoid Arthritis: A French and International (VigiBase) Signal Detection Study. <i>Clinical Pharmacology and Therapeutics</i> , 2023, 113, 1107-1116.	2.3	5
307	Immunogenicity and Safety of Vaccines Against Coronavirus Disease in Actively Treated Patients with Solid Tumors: A Prospective Cohort Study. <i>Cancer Research and Treatment</i> , 0, , .	1.3	2
308	No association of malignant B-cell non-Hodgkin lymphomas with ipsilateral SARS-CoV-2 vaccination. <i>Cancer Medicine</i> , 0, , .	1.3	1
309	Adenoviral Vector-Based Vaccine Platform for COVID-19: Current Status. <i>Vaccines</i> , 2023, 11, 432.	2.1	17
310	A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines. <i>Cell Reports Medicine</i> , 2023, 4, 100971.	3.3	4
311	Introductory Chapter: Global Research Efforts toward the Development of COVID-19 Vaccines. , 0, , .		0

#	ARTICLE	IF	CITATIONS
312	Dynamics of SARS-CoV-2 Spike-IgG throughout Three COVID-19 Vaccination Regimens: A 21-Month Longitudinal Study of 82 Norwegian Healthcare Workers. <i>Viruses</i> , 2023, 15, 619.	1.5	1
313	Safety and incidence of COVID-19 following ChAdOx1(AZD1222) COVID-19 vaccination in Botswana. <i>Journal of Infection</i> , 2023, , .	1.7	1
314	SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders: A prospective, real-life Belgian cohort study – the BELCOMID study. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2
315	A systematic review and meta-analysis of the effectiveness and safety of COVID-19 vaccination in older adults. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	10
316	Encephalitis following COVID-19 Vaccination: A Systematic Review. <i>Vaccines</i> , 2023, 11, 576.	2.1	7
317	Impact of Vaccination and the Omicron Variant on COVID-19–related Chest CT Findings: A Multicenter Study. <i>Radiology</i> , 2023, 307, .	3.6	11
318	Real-World COVID-19 Vaccine Protection Rates against Infection in the Delta and Omicron Eras. <i>Research</i> , 2023, 6, .	2.8	0
319	Retrospective, Observational Studies for Estimating Vaccine Effects on the Secondary Attack Rate of SARS-CoV-2. <i>American Journal of Epidemiology</i> , 0, , .	1.6	1
320	Immune correlates analysis of a phase 3 trial of the AZD1222 (ChAdOx1 nCoV-19) vaccine. <i>Npj Vaccines</i> , 2023, 8, .	2.9	13
321	Indirect Dispersion of SARS-CoV-2 Live-Attenuated Vaccine and Its Contribution to Herd Immunity. <i>Vaccines</i> , 2023, 11, 655.	2.1	3
322	COVID-19 Vaccination Safety Profiles in Patients With Solid Tumour Cancers: A Systematic Review. <i>Clinical Oncology</i> , 2023, , .	0.6	2
323	Gender inequity and COVID-19 vaccination policies for pregnant women in the Americas. <i>Wellcome Open Research</i> , 0, 8, 121.	0.9	0
324	Population pharmacokinetics and exposure–response analysis of a single dose of sotrovimab in the early treatment of patients with mild to moderate COVID-19. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2023, 12, 853-864.	1.3	2
325	Longitudinal Profiles of Anti-Platelet Factor 4 Antibodies in Thai People Who Received ChAdOx1 nCoV-19 Vaccination. <i>Vaccines</i> , 2023, 11, 692.	2.1	3
326	The effect of HIV on COVID-19 vaccine responses. <i>Current Opinion in HIV and AIDS</i> , 2023, 18, 135-141.	1.5	4
327	Low humoral and cellular immune responses early after breakthrough infection may contribute to severe COVID-19. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	3
328	Antibody-mediated protection against symptomatic COVID-19 can be achieved at low serum neutralizing titers. <i>Science Translational Medicine</i> , 2023, 15, .	5.8	12
329	Immunogenicity and Safety of Homologous and Heterologous Prime-Boost of CoronaVac® and ChAdOx1 nCoV-19 among Hemodialysis Patients: An Observational Prospective Cohort Study. <i>Vaccines</i> , 2023, 11, 715.	2.1	1

#	ARTICLE	IF	CITATIONS
330	Immunogenicity of a spike protein subunit-based COVID-19 vaccine with broad protection against various SARS-CoV-2 variants in animal studies. <i>PLoS ONE</i> , 2023, 18, e0283473.	1.1	2
331	A Novel Approach to Obtain Vaccine Effectiveness Continuous Profiles. Example Case: COVID-19 in Elderly Mexicans. <i>Vaccines</i> , 2023, 11, 719.	2.1	1
332	Protection from SARS-CoV-2 Variants by MVAs expressing matched or mismatched S administered intranasally to mice. <i>Npj Vaccines</i> , 2023, 8, .	2.9	1
333	Autoimmune liver diseases and SARS-CoV-2. <i>World Journal of Gastroenterology</i> , 0, 29, 1838-1851.	1.4	7
334	Salivary Antibody Responses to Two COVID-19 Vaccines following Different Vaccination Regimens. <i>Vaccines</i> , 2023, 11, 744.	2.1	1
335	<sc>ChAdOx1 nCoV</sc> â€19 vaccination generates spikeâ€specific <sc>CD8</sc> ⁺ T cells in aged mice. <i>Immunology and Cell Biology</i> , 0, , .	1.0	0
336	Signal detection of <sc>COVID</sc> â€19 vaccines adverse events using spontaneous reports from South Korea. <i>Pharmacoepidemiology and Drug Safety</i> , 0, , .	0.9	0
337	A SARS-CoV-2 Vaccine Designed for Manufacturability Results in Unexpected Potency and Non-Waning Humoral Response. <i>Vaccines</i> , 2023, 11, 832.	2.1	1
338	A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned. <i>PLoS Pathogens</i> , 2023, 19, e1011298.	2.1	5
352	Diabetes and Infection. , 2023, , 755-785.		0
383	Genetic-Based Vaccine Vectors. , 2023, , 1374-1396.e11.		0
406	Protection of COVID-19 vaccine in general and special population. , 2023, , .		0
408	Traditional Herbal Medicines and Their Active Constituents in Combating SARS-CoV-2 Infection. , 2023, , 137-188.		0
410	Effects of Biological Sex and Pregnancy on SARS-CoV-2 Pathogenesis and Vaccine Outcomes. <i>Current Topics in Microbiology and Immunology</i> , 2023, , 75-110.	0.7	0
456	Intervention Trials. , 2024, , 1-30.		0